EFFECTS OF A YERBA MATE EXTRACT IN REDUCING METABOLIC SYNDROME IN OVERWEIGHT INDIVIDUALS

NCT07000825 | Enrolling By Invitation DMC

• 1 other identifier: 84742724.6.0000.5564
• Study Type: interventional
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

Yerba mate (Ilex paraguariensis), a traditional drink consumed in different parts of the word, but especially in southern Brazil, is an importante source of polyphenols and has a high antioxidant potencial, With a moderate content of methylxanthines, yerba mate has stood out for its promising effects in modulating metabolic pathways in pre-clinical models. However, its beneficial effets in clinical trials have yet to be elucidated. Overweight and chronic non-communicable diases are urgent public health conditions and reducing the risk of these conditions through food sources is one of the most sustainable approaches. This study aims to evaluate the impact of a standardized extract of yerba mate on nutritional, biochemical, metabolic, inflammatory and antioxidant status parameters in overweight individuals compared to a placebo. A double-blind, parallel, randomized, placebo- controlled clinical trial will be conducted involving 80 overweight individuals. The subjects will receive an encapsulated yerba mate extract totaling 2,250 mg or a corresponding placebo, fractionated three times a day. This amount was defined according to previous studies thet estimated the habitual intake of yerba mate in the form of chimarrão or tererê by adults in a city in the southern region of the country. Anthropometric measurements, composition, blood pressure and blod and stool samples will be collected for nutritional assessment, metabolic and inflammatory parameters and antioxidant status assessment on days 0 and 90. The data will be analyzed descriptively and inferentially. Differences in the individuals characteristics at baseline and comparisons between groups will be aseessed using the difference of means test (depending on the normality of the data) and chi-square or Fisher-s exact test for categorical variabes, In addition, to compare the effect of the intervention between the groups, a two-way analysis of covariance will be used. A 5% significance level will be adopted. It is expect to find positive effects of yerba mate extract on the parameters assessed.

Conditions

Diabetes; Oxidative Stress; Dyslipidemia; Inflamation; Metabolic Syndrome

Keywords

glycemic control; lipid metabolism; oxidative stress; metabolic syndrome; adipose tissue

Outcome Measures

Primary Outcomes (6)

• body mass index

  measured by weight in kilograms and height in meters

  12 weeks

• fat percentage

  measured by electrical bioimpedance

  12 weeks

• diabetes

  measured by plasma glucose, fructosamine and C peptide

  12 weeks

• abdominal fat

  measured by waist circumference

  12 weeks

• dyslipidemia

  measured by lipid profile

  12 weeks

• diabetes

  measured by insulin levels

  12 weeks

Secondary Outcomes (8)

• inflamation

  12 weeks

• oxidative stress

  12 weeks

• oxidative stress

  12 weeks

• oxidative stress

  12 weeks

• transcriptome

  12 weeks

Study Arms (2)

Intervention (yerba mate)

EXPERIMENTAL

2,250 mg of standardized yerba mate extract will be administered in 9 capsules, 3 times a day, just before the main meals.

Dietary Supplement: Intervention with yerba mate extract or placebo

Test (yerba mate)

PLACEBO COMPARATOR

9 capsules containing maltodextrin will be administered 3 times a day, just before the main meals.

Dietary Supplement: Intervention with yerba mate extract or placebo

Interventions

Intervention with yerba mate extract or placebo DIETARY_SUPPLEMENT

The standardized extract of yerba mate (Ilex paraguariensis) will be supplied by Sustentec. It is a dry extract of the plant's green, powdered leaves, obtained through aqueous extraction. The extract was obtained by infusing the dried leaves of the plant and the drying process was carried out using a spray-dryer (ratio 6/1 leaves/extract). The extract will be encapsulated containing 250 mg each. Administration Intervention group: 2,250 mg of standardized yerba mate extract will be administered in 9 capsules, 3 times a day, just before the main meals. This amount will provide approximately 980 mg of caffeoylquinic acids/day, which was defined based on the estimated usual intake of caffeoylquinic acids by individuals in a municipality in the southern region of the country, from traditional drinks made with yerba mate (chimarrão and tereré) (Gebara et al., 2017). Placebo group: 9 capsules containing maltodextrin will be administered 3 times a day, just before the main meals.

Intervention (yerba mate); Test (yerba mate)

Eligibility Criteria

• Age: 40 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• men and women;
• aged between 40 and 65 years;
• with no previous cardiovascular history;
• individuals who are non-smokers or who have stopped smoking in the last 3 years;
• individuals who agree to maintain a habitual diet and physical activity;
• individuals who agree to maintain habitual consumption of polyphenol-rich beverages (yerba mate, teas, coffee, wine, cocoa, soy milk and fruit juice) during the course of the study;
• individuals who are not taking hypoglycemic, antihypertensive or anticholesterolemic drugs and;
• individuals who are overweight or obese (BMI≥25 to 34 Kg/m2 );
• individuals who have given up nutritional monitoring at least 3 months or who are undergoing nutritional treatment, but who are not showing weight changes of \>5% in the last 3 months.

You may not qualify if:

• diagnosis uncontrolled metabolic or endocrine pathologies;
• who have undergone obesity surgery;
• post-menopausal women;
• pregnant and breastfeeding women;
• use of antipsychotics;
• with a vegetarian or vegan diet;
• who use probiotics and food supplements with antioxidant characteristics;
• those who have had a weight change of more than 10% in the last 3 months; 9) in treatment for excess body weight (hypocaloric diet or current nutritional treatment);
• \) smokers or chronic alcoholics; 11) Severe hypertension, history of cardiovascular disease with clinical complications such as: acute myocardial infarction and other coronary heart disease; 12) individuals with known malignant neoplasms, gastrointestinal diseases, kidney disease and/or liver disease.

Sponsors & Collaborators

• Universidade Federal da Fronteira Sul: lead
• Itaipu Technological Park (ITP): collaborator
• Fundação Araucária: collaborator

Study Sites (1)

Universidade Federal da Fronteira Sul

Realeza, Paraná, 85770-000, Brazil

Location

MeSH Terms

Conditions

Metabolic Syndrome; Diabetes Mellitus; Dyslipidemias

Interventions

Methods

Condition Hierarchy (Ancestors)

Insulin Resistance; Hyperinsulinism; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases; Lipid Metabolism Disorders

Intervention Hierarchy (Ancestors)

Investigative Techniques

Study Officials

• Eloá A Koehnlein, Doctorate

  Universidade Federal da Fronteira Sul

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Model Details: This is a randomized, double-blind, parallel-group clinical trial with a 90-day intervention. The trial will be registered with the Brazilian Clinical Trial Registry - Ministry of Health (https://ensaiosclinicos.gov.br/) and will be conducted in accordance with the CONSORT guidelines (Schulz KF, Altman DG, Moher D, for CONSORT Group. CONSORT Statement 2010: updated guidelines for reporting parallel-group randomized trials). The clinical trial will be conducted from March 2025 to July 2026.

Study Record Dates

• First Submitted: March 17, 2025
• First Posted: June 3, 2025
• Study Start: October 6, 2025
• Primary Completion (Estimated): December 1, 2027
• Study Completion (Estimated): December 1, 2029
• Last Updated: May 29, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

BR (1)